Oncology
Recurrent or Metastatic Solid Tumors
1
Pipeline Programs↗
3
Active Trials↗
3
Companies Involved↗
Recurrent or Metastatic Solid Tumors is an early-stage landscape with 1 program across 3 companies. The most active players are AstraZeneca, Daiichi Sankyo, Roche.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
7
clinical trials
Completed3 · 43%
Recruiting3 · 43%
Unknown status1 · 14%
Clinical Trials
Trial Activity
7 trials
T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors
Recruiting·—·Phase 1/2·NCT05200559·70 enrolled
Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
Completed·—·Phase 1·NCT02013492·1 enrolled
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00526149·76 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)